<div id="readability-page-1"><div>HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.Travere Therapeutics, is a Nasdaq-listed US biopharmaceutical company (NASDAQ: TVTX) with a focus on the field of rare glomerular diseases, particularly targeting IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The company is also developing therapeutic programs for rare genetic metabolic diseases, such as homocystinuria (HCU). Its core product, FILSPARI'(sparsentan) is the first and only medicine approved by the FDA for the treatment of FSGS, further strengthening the company's leading position in the renal therapy sector.Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. As an investigational oral, covalent reversible BTK inhibitor, civorebrutinib is designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney disease. Driven by strong clinical development capabilities, Everest Medicines has recently achieved several key milestones in global multi-center trials, in-house R&amp;D pipeline validation, and international licensing partnerships. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up.EVER001 possesses therapeutic development potential in multiple immune-mediated glomerular diseases, including PMN, IgA nephropathy, MCD, FSGS, and lupus nephritis. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. EVER001 is expected to offer a new treatment option for more than 10 million affected patients globally. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications.'This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,' said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. 'As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&amp;D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.''Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,' said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. 'Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.'This cooperation between Everest Medicines and Travere Therapeutics further propels the globalization of EVER001, reflecting the continued unlocking of the value of Everest Medicines innovative drugs. Currently, Everest Medicines has established a comprehensive renal product matrix inclding Nefecon', MT1013, and EVER001, spanning indications such as IgA nephropathy, secondary hyperparathyroidism (SHPT), and a wide range of immune-mediated kidney diseases. By continuously deepening its strategic layout in nephrology, Everest Medicines is accelerating its global footprint to provide accessible and reliable treatment solutions for more patients through innovative therapies.Source: Everest Medicines LimitedCopyright 2026 ACN Newswire . All rights reserved.</div></div>

01952

TVTX

Everest Medicines announced an exclusive licensing agreement with Travere Therapeutics for civorebrutinib, a potential best-in-class BTK inhibitor for rare kidney diseases. Everest will receive an $112.5 million upfront payment and up to $1.03 billion in milestone payments, plus tiered royalties. The deal covers development and commercialization outside China. Civorebrutinib targets immune-mediated kidney diseases like PMN, IgA nephropathy, and FSGS.

Asian Corporate Newswire

EVEREST MED

Travere Therapeutics

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion